Generic Competition in the US Pharmaceutical Industry

How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry

Explaining Vertical Integration in the Generic Pharmaceutical Industry

This paper explores the motives for vertical integration in the US generic pharmaceutical industry. There is some evidence of strategic complementarity: a firm is more likely to enter a generic drug market in a vertically integrated manner if it expects a higher degree of vertical integration among rivals. This suggests that vertical integration is characterized by bandwagon behavior. While ban...

Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry

THE ETHICAL PHARMACEUTICAL industry is an important one, not so much for its economic size as for the benefits that it delivers to users of its products. The industry has been transformed structurally since the 1940s from a producer of selected chemicals to a research-oriented sector that makes a major contribution to the technology of health care. I Its very success in generating a stream of n...

A Blow to Free Competition in the Chilean Pharmaceutical Industry

The charge made by the Court led to an exhaustive investigation by the Fiscalia Nacional Economica (FNE), the national prosecutor for economic crimes, which oversees free competition in the country. The agency used documents and telephone calls to prove that during that time period, the three chains agreed clandestinely to raise the price of some medications by as much as 97%. Most notably, thi...

Updated trends in US brand-name and generic drug competition.

OBJECTIVE To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent challenges; and generic drug penetration. METHODS This study used IMS Health National Sales Perspectives(TM) US data to calculate MEPs...